Farxiga Approval Expands Use to More Patients With Heart Failure
Dapagliflozin is sodium-glucose cotransporter 2 inhibitor.
Diagnosis & Disease Information
Intramuscular Testosterone Linked to Rise in Hematocrit
The risk of hematocrit elevation may depend on testosterone therapy’s route of administration, according to investigators.
Healthy Diets Fail to Improve Survival Outcomes in the ESKD Population
Investigators report no significant improvement in cardiovascular or overall mortality in patients on dialysis.
Artificial Intelligence Has Potential to Improve Clinical Medicine
Investigators report promising results with an AI algorithm that can identify and distinguish between 2 heart conditions that challenge even expert cardiologists.
In-Hospital Cardiac Arrest and Death in Children With Cardiac Disease
Researchers sought to evaluate incidence of in-hospital cardiac arrest and mortality in children with cardiac disease admitted to the ICU.
COVID-19 Linked to Cardiovascular Disease, Mortality Risk
A study was conducted to determine short- and long-term risk for cardiovascular disease and mortality in patients with a medical history of COVID-19.
Depression, Poor Mental Health and CVD Risk In Younger Adults
A study was conducted to determine the effect of depression and poor mental health on cardiovascular health in younger adults in the United States.
Kidney Biopsy Findings Predict Risk of Cardiovascular Events in CKD
Histologic lesions in the kidney may reflect systemic processes that lead to cardiovascular events, according to investigators.
Olezarsen Fast Tracked for Familial Chylomicronemia Syndrome
Olezarsen is an investigational LICA antisense medication designed to inhibit the production of apoC-III for patients at risk of disease due to elevated triglyceride levels.
Wearable Furosemide Delivery System Furoscix Now Available
Furoscix is a pH-neutral formulation of furosemide, a loop diuretic, designed for SC administration via an on-body infusor for outpatient self-administration.
- Loading...
Loading...
Next post in News
Loading... 
Loading...